Literature DB >> 2469222

Familial amyloidotic polyneuropathy.

M D Benson.   

Abstract

Amyloidosis has received considerable attention recently because of its association with Alzheimer's disease. Actually, the amyloid in the cortical plaques, which is characteristic of Alzheimer's disease, is a localized form of amyloid deposition. Although intracranial vascular amyloid deposits which contain the A4 or beta-protein are usually associated with Alzheimer's disease, deposition of this amyloid fibril substance in other organs of the body has not been described. Much less attention has been paid to amyloid involvement of the PNS which is a fascinating subject in itself and is the subject of this review.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469222     DOI: 10.1016/0166-2236(89)90162-8

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  27 in total

1.  Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry.

Authors:  E J Nettleton; P Tito; M Sunde; M Bouchard; C M Dobson; C V Robinson
Journal:  Biophys J       Date:  2000-08       Impact factor: 4.033

2.  Complement neoantigen and vitronectin are components of plaques in amyloid AL neuropathy.

Authors:  G L Zanusso; G Moretto; B Bonetti; S Monaco; N Rizzuto
Journal:  Ital J Neurol Sci       Date:  1992-09

3.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

4.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

5.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

Review 6.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 7.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

Review 8.  Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).

Authors:  Yukio Ando
Journal:  Med Mol Morphol       Date:  2005-09       Impact factor: 2.309

9.  AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.

Authors:  Sravan C Penchala; Stephen Connelly; Yu Wang; Miki S Park; Lei Zhao; Aleksandra Baranczak; Irit Rappley; Hannes Vogel; Michaela Liedtke; Ronald M Witteles; Evan T Powers; Natàlia Reixach; William K Chan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef; Mamoun M Alhamadsheh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

Review 10.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.